First Patient Treated in INB-400 Phase 2 GBM Trial

IN8bio, a biopharmaceutical firm, has marked a significant step in the treatment of glioblastoma multiforme (GBM), a highly aggressive brain cancer, with the commencement of dosing in its Phase 2 clinical trial for INB-400. The first patient received the treatment at the Cleveland Clinic in Ohio. INB-400 is an autologous gamma-delta T cell therapy that has been genetically modified to endure chemotherapy and retain its inherent capability to identify and destroy cancer cells when used alongside standard treatments like temozolomide.

The CEO of IN8bio, William Ho, highlighted the importance of this trial's initiation for patients with GBM who have limited treatment options. He emphasized the innovative approach of combining engineered gamma-delta T cells with standard treatments to potentially enhance patient outcomes. Gamma-delta T cells are unique immune cells that can distinguish between healthy and cancerous tissues, playing a crucial role in the immune system by bridging innate and adaptive responses, leading to direct tumor cell killing and immune memory.

The Phase 2 study aims to assess the safety and tolerability of INB-400 in combination with temozolomide for newly diagnosed GBM patients. The trial's primary goal is to measure the overall survival rate at 12 months, with secondary goals encompassing safety, response rate, time to progression, and progression-free survival.

Since 2005, the standard treatment for GBM has been surgery followed by radiation, chemotherapy, and temozolomide therapy. However, most patients relapse within six to seven months, and few survive beyond five years. INB-400 is designed to resist chemotherapy, allowing it to work with temozolomide to boost immune responses and eliminate cancer cells more effectively.

IN8bio's lead program, INB-400, has received Orphan Drug Designation from the FDA, recognizing its potential as the first genetically modified gamma-delta T cell therapy for GBM. The company is dedicated to developing immunotherapies that leverage the unique properties of gamma-delta T cells to target cancer. IN8bio's pipeline includes additional trials for solid and hematologic tumors, showcasing the company's commitment to advancing cancer treatments.